What drug class does Vebreltinib belong to?

Vebreltinib is an innovative targeted anti-cancer drug that belongs to the Tyrosine Kinase Inhibitor (TKI) family. It mainly targets tumor types with abnormal MET signaling pathways for precise treatment. The MET signaling pathway is abnormally activated in a variety of tumors, especially in patients with non-small cell lung cancer (NSCLC) and some brain gliomas. Abnormal activation can promote tumor cell proliferation, migration, and invasion, and may lead to the development of drug resistance. Bripretinib selectively inhibits MET receptor tyrosine kinase activity and blocks tumor growth signals, thereby exerting a precise anti-tumor effect and providing a new clinical treatment strategy for patients with MET abnormalities.

In non-small cell lung cancer, boricitinib is specifically targeted to patients with locally advanced or metastatic disease who have mesenchymal-epithelial transforming factor (MET) exon 14 skipping. MET exon 14 skipping can lead to abnormal stability and functional overactivation of MET protein, which is directly involved in tumor progression. Traditional chemotherapy or immunotherapy has limited efficacy in such patients, and the precise targeted inhibition of bripretinib can significantly interfere with this signaling pathway, providing patients with higher treatment selectivity and predictability of efficacy. In clinical applications, it is usually necessary to confirm the MET exon 14 jump status through genetic testing to achieve personalized and precise medication.

In the field of brain glioma, boricitinib is suitable for adult patients with IDH-mutant astrocytoma (WHO grade 4) or low-grade glioblastoma who have failed previous treatment and have thePTPRZ1-MET fusion gene. The presence of PTPRZ1-MET fusion gene will lead to abnormal activation of the MET signaling pathway, thereby promoting the growth and drug resistance of glioma. By inhibiting this pathway, buricitinib can not only slow down tumor progression, but also provide new treatment opportunities for patients with gliomas with high recurrence rates and difficult treatment. Such patients also need to undergo genetic testing before use to ensure that the PTPRZ1-MET fusion gene is indeed present in the tumor to ensure the targeting and efficacy of the drug.

Reference materials:https://www.asymbio.com.cn/